正在加载视频...

视频加载失败

加载此视频时出现问题。这可能是由于临时网络问题，或视频可能不可用。

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

Mark Lewis, MD, FASCO

96,054 subscribers

1,179,857 次观看 • 3 个月前 •via X (Twitter)

健康养生科学技术 #ASCO26

Anya Rossi• Live Now

Private livecam show

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%

Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%

Masahiro TORASAWA, MD. PhD.

12,917 次观看 • 3 个月前

The recent breakthrough in pancreatic cancer therapy isn't a cure. But it *may be* a pathway to one. Pancreatic cancer has miserable survival rates. Most cases are driven by RAS, a protein long considered basically undruggable. Revolution Medicines found a way to target RAS with daraxonrasib, which nearly doubled median overall survival versus chemo, and was easier to tolerate. Crucially, being able to target RAS gives pancreatic cancer therapy a new foundation. Other drugs can be layered on top of daraxonrasib to even better results than the drug alone. Samuel Hume explains:

The recent breakthrough in pancreatic cancer therapy isn't a cure. But it may be a pathway to one. Pancreatic cancer has miserable survival rates. Most cases are driven by RAS, a protein long considered basically undruggable. Revolution Medicines found a way to target RAS with daraxonrasib, which nearly doubled median overall survival versus chemo, and was easier to tolerate. Crucially, being able to target RAS gives pancreatic cancer therapy a new foundation. Other drugs can be layered on top of daraxonrasib to even better results than the drug alone. Samuel Hume explains:

TBPN

62,355 次观看 • 2 个月前

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

Dana-Farber

60,803 次观看 • 3 个月前

An experimental drug called daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a newly published study. Jonathan LaPook, M.D has more on the findings.

An experimental drug called daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a newly published study. Jonathan LaPook, M.D has more on the findings.

CBS Evening News with Tony Dokoupil

28,256 次观看 • 3 个月前

Hemotional results. Dedicate to all patients with pancreatic cancer. Results like this one makes me a better clinical investigator and physician when I’ll go back in clinic next week.

Hemotional results. Dedicate to all patients with pancreatic cancer. Results like this one makes me a better clinical investigator and physician when I’ll go back in clinic next week.

Antonio Giordano, MD PhD

57,826 次观看 • 3 个月前

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Dr. Cathy Eng Sumanta K. Pal, MD, FASCO Tom Powles Brian Rini, MD Daniel Castellano gilberto lopes Petros Grivas Dra. María Natalia Gandur Quiroga Emre Yekedüz Neeraj Agarwal, MD, FASCO ASCO ONCOassist® | The go-to oncology app Open Medicine @MedwatchKate Simon C 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 UroToday.com OncLive.com Cristiane D Bergerot, PhD, FASCO International Urology Cancer Summit Dr Amol Akhade LARVOL IMG Oncologists

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Dr. Cathy Eng Sumanta K. Pal, MD, FASCO Tom Powles Brian Rini, MD Daniel Castellano gilberto lopes Petros Grivas Dra. María Natalia Gandur Quiroga Emre Yekedüz Neeraj Agarwal, MD, FASCO ASCO ONCOassist® | The go-to oncology app Open Medicine @MedwatchKate Simon C 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 UroToday.com OncLive.com Cristiane D Bergerot, PhD, FASCO International Urology Cancer Summit Dr Amol Akhade LARVOL IMG Oncologists

Yüksel Ürün

217,928 次观看 • 3 个月前

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Camus

615,893 次观看 • 1 年前

Fenbendazole cured this man of stage 4 lung cancer in 8 months. If you ever get diagnosed with cancer, do not hesitate to follow the Joe Tippens protocol. It's a game changer. I used it to cure my cancer, I used it on my wife and on many other patients around the world. Testimonies like this need to be heard worldwide, so I encourage you all to share this video and tag my page to reach a wider audience so that many patients can become familiar with this protocol. Patients need to see testimonies like this, so share my page to reach more patients because I will be updating you with great testimonials like this. #Fenbendazole #Ivermectin #Cancer #Joetippensprotocol

Fenbendazole cured this man of stage 4 lung cancer in 8 months. If you ever get diagnosed with cancer, do not hesitate to follow the Joe Tippens protocol. It's a game changer. I used it to cure my cancer, I used it on my wife and on many other patients around the world. Testimonies like this need to be heard worldwide, so I encourage you all to share this video and tag my page to reach a wider audience so that many patients can become familiar with this protocol. Patients need to see testimonies like this, so share my page to reach more patients because I will be updating you with great testimonials like this. #Fenbendazole #Ivermectin #Cancer #Joetippensprotocol

Dr. Zakaria MD

24,261 次观看 • 2 个月前

🚨 THE CURE FOR CANCER HAS JUST BEEN APPROVED - BUT NOT FOR AMERICANS Dr. Patrick Soon-Shiong went on air with Chris Cuomo and dropped a claim that should’ve stopped the country cold. He says a universal cancer treatment - shown to extend survival in lung, breast, pancreatic, and even glioblastoma - already exists. The molecule (IL-15) was flagged over a decade ago as one of the most promising cancer-killing candidates ever. The trials exist. The survival data exists. According to him, Saudi Arabia reviewed the science and approved it for lung cancer, while in the U.S., the exact same drug is still restricted to a tiny bladder-cancer use. More than 13,000 patients are now reportedly requesting access. Same drug. Same data. Different outcome. If this can save lives, who decided Americans don’t deserve it yet?

🚨 THE CURE FOR CANCER HAS JUST BEEN APPROVED - BUT NOT FOR AMERICANS Dr. Patrick Soon-Shiong went on air with Chris Cuomo and dropped a claim that should’ve stopped the country cold. He says a universal cancer treatment - shown to extend survival in lung, breast, pancreatic, and even glioblastoma - already exists. The molecule (IL-15) was flagged over a decade ago as one of the most promising cancer-killing candidates ever. The trials exist. The survival data exists. According to him, Saudi Arabia reviewed the science and approved it for lung cancer, while in the U.S., the exact same drug is still restricted to a tiny bladder-cancer use. More than 13,000 patients are now reportedly requesting access. Same drug. Same data. Different outcome. If this can save lives, who decided Americans don’t deserve it yet?

HustleBitch

2,307,726 次观看 • 7 个月前

Right now, I know you’re busy taking care of everyone else, but when was the last time you took care of yourself? This Breast Cancer Awareness Month, Lifetime and I are encouraging you to talk to a doctor about whether it’s time for your mammogram or other cancer screenings.

Right now, I know you’re busy taking care of everyone else, but when was the last time you took care of yourself? This Breast Cancer Awareness Month, Lifetime and I are encouraging you to talk to a doctor about whether it’s time for your mammogram or other cancer screenings.

Jill Biden Archived

464,352 次观看 • 2 年前

In an interview, Dr. Kathleen Ruddy, a distinguished breast cancer surgeon, author, and inventor, shared groundbreaking insights on repurposed drugs for cancer treatment. She discussed how medications like ivermectin, mebendazole, sildenafil, metformin, aspirin, doxycycline, and vitamin C show promise in targeting cancer stem cells, the drivers of tumor regrowth. “Cancer stem cells are the real bad boys,” Dr. Ruddy stated, explaining that chemotherapy and radiation often fail to eliminate them, leading to cancer recurrence. Preclinical studies show combinations like doxycycline and vitamin C can eradicate over 90% of cancer stem cells, with doxycycline, azithromycin, and vitamin C proving equally effective. These affordable, FDA-approved drugs could halt tumors without harming patients. Dr. Ruddy praised Dr. Paul Marik’s Cancer Care monograph as a must-read for its analysis of repurposed drugs. Her mission is to cure cancer, not manage it as a chronic disease. “Patients want to live without cancer,” she emphasized. Through her work, she’s studying these therapies’ impact on cancers like breast, prostate, and lung. “Kill the cancer, or the cancer will kill you,” Dr. Ruddy urged. Could repurposed drugs transform cancer care?

In an interview, Dr. Kathleen Ruddy, a distinguished breast cancer surgeon, author, and inventor, shared groundbreaking insights on repurposed drugs for cancer treatment. She discussed how medications like ivermectin, mebendazole, sildenafil, metformin, aspirin, doxycycline, and vitamin C show promise in targeting cancer stem cells, the drivers of tumor regrowth. “Cancer stem cells are the real bad boys,” Dr. Ruddy stated, explaining that chemotherapy and radiation often fail to eliminate them, leading to cancer recurrence. Preclinical studies show combinations like doxycycline and vitamin C can eradicate over 90% of cancer stem cells, with doxycycline, azithromycin, and vitamin C proving equally effective. These affordable, FDA-approved drugs could halt tumors without harming patients. Dr. Ruddy praised Dr. Paul Marik’s Cancer Care monograph as a must-read for its analysis of repurposed drugs. Her mission is to cure cancer, not manage it as a chronic disease. “Patients want to live without cancer,” she emphasized. Through her work, she’s studying these therapies’ impact on cancers like breast, prostate, and lung. “Kill the cancer, or the cancer will kill you,” Dr. Ruddy urged. Could repurposed drugs transform cancer care?

Camus

117,774 次观看 • 1 年前

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

422,189 次观看 • 10 个月前

A New Dawn in the Cancer War: Pioneering "BioShield" Technology Achieves Long-Term Remission Where Others Failed A stunning revelation from Dr. Patrick Soon-Shiong on the dawn of a new medical era. He details a breakthrough he calls "BioShield," a technology designed to prevent cancer by fundamentally educating the body's own immune system. Forget conventional vaccines. This isn't about antibodies. This is about creating a living, intelligent defense system within you. Here’s the concept: "BioShield" educates your T-cells to become elite "memory" cells. They then hide in your bone marrow, lying in wait. When a cancerous cell appears, they emerge to seek and destroy it—stopping cancer before it can ever gain a foothold. This isn't science fiction. It's peer-reviewed, published science with the National Cancer Institute (NCI). And the results are nothing short of remarkable: ➡️ Bladder Cancer: Patients who failed all other treatments and faced radical bladder removal have achieved complete remission for nine years after a simple injection. No surgery. Just a functional cure. ➡️ Pancreatic Cancer: A disease with a grim prognosis, now seeing patients disease-free for five years. The late Senator Harry Reid, after being told by others not to pursue it, saw his tumor markers normalize and lived two active, cancer-free years. ➡️ Merkel Cell Carcinoma & Head/Neck Cancer: Stories of complete responses in patients given weeks to live, with one living nine years and another saved from hospice when his ulcerating tumor melted away. Dr. Soon-Shiong is reframing the conversation. This isn't a "vaccine" in the traditional sense. It's Project BioShield—a proactive, cellular guardian for the body. The takeaway? We are transitioning from toxic, reactive cancer therapies to intelligent, preemptive protection. The age of the immune system as our most powerful shield against cancer has arrived. What are your thoughts on this "BioShield" approach to cancer?

A New Dawn in the Cancer War: Pioneering "BioShield" Technology Achieves Long-Term Remission Where Others Failed A stunning revelation from Dr. Patrick Soon-Shiong on the dawn of a new medical era. He details a breakthrough he calls "BioShield," a technology designed to prevent cancer by fundamentally educating the body's own immune system. Forget conventional vaccines. This isn't about antibodies. This is about creating a living, intelligent defense system within you. Here’s the concept: "BioShield" educates your T-cells to become elite "memory" cells. They then hide in your bone marrow, lying in wait. When a cancerous cell appears, they emerge to seek and destroy it—stopping cancer before it can ever gain a foothold. This isn't science fiction. It's peer-reviewed, published science with the National Cancer Institute (NCI). And the results are nothing short of remarkable: ➡️ Bladder Cancer: Patients who failed all other treatments and faced radical bladder removal have achieved complete remission for nine years after a simple injection. No surgery. Just a functional cure. ➡️ Pancreatic Cancer: A disease with a grim prognosis, now seeing patients disease-free for five years. The late Senator Harry Reid, after being told by others not to pursue it, saw his tumor markers normalize and lived two active, cancer-free years. ➡️ Merkel Cell Carcinoma & Head/Neck Cancer: Stories of complete responses in patients given weeks to live, with one living nine years and another saved from hospice when his ulcerating tumor melted away. Dr. Soon-Shiong is reframing the conversation. This isn't a "vaccine" in the traditional sense. It's Project BioShield—a proactive, cellular guardian for the body. The takeaway? We are transitioning from toxic, reactive cancer therapies to intelligent, preemptive protection. The age of the immune system as our most powerful shield against cancer has arrived. What are your thoughts on this "BioShield" approach to cancer?

Camus

31,209 次观看 • 9 个月前

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Joe Tippens

46,807 次观看 • 1 个月前

American “I'm a doctor and I'm unhappy with our current US health system” She started looking into the UK universal healthcare system wait time for cancer - In the UK cancer patients just be seen within 62 days but only 65% of people are seen within that time - In America cancer patients are seen within 30 days “There's a way and that's kind of a scary thing.” She goes into cancer survival rates by country, and the US isn’t anywhere near the top This is interesting information. We need healthcare reform

American “I'm a doctor and I'm unhappy with our current US health system” She started looking into the UK universal healthcare system wait time for cancer - In the UK cancer patients just be seen within 62 days but only 65% of people are seen within that time - In America cancer patients are seen within 30 days “There's a way and that's kind of a scary thing.” She goes into cancer survival rates by country, and the US isn’t anywhere near the top This is interesting information. We need healthcare reform

Wall Street Apes

80,976 次观看 • 8 个月前

🚨Did you know that fructose can fuel cancer by hijacking your liver? (🔗 at end) 1/5) It sounds dramatic, but new research - published in nature has uncovered a chilling new connection between fructose and cancer growth. And it’s not just about sugar making us gain weight; the effects are far deeper and more direct. 🧵Let me break it down. But first, background… High fructose diets are already associated with increased risks of certain cancer, like pancreatic cancer. And there are many known mechanisms whereby fructose can support cancer growth and survival. 🤨But I particularly like these new data, because they reveal just how sneaky cancer can be, effectively hijacking the liver for its own purposes

🚨Did you know that fructose can fuel cancer by hijacking your liver? (🔗 at end) 1/5) It sounds dramatic, but new research - published in nature has uncovered a chilling new connection between fructose and cancer growth. And it’s not just about sugar making us gain weight; the effects are far deeper and more direct. 🧵Let me break it down. But first, background… High fructose diets are already associated with increased risks of certain cancer, like pancreatic cancer. And there are many known mechanisms whereby fructose can support cancer growth and survival. 🤨But I particularly like these new data, because they reveal just how sneaky cancer can be, effectively hijacking the liver for its own purposes

Nick Norwitz MD PhD

49,038 次观看 • 1 年前

MORE YOUNG PEOPLE ARE GETTING CANCER Kate Middleton’s revelation that she is being treated for cancer has spotlighted an alarming increase in cancer among young people. Cancer specialist: “When I started as a cancer surgeon 20 years ago, you rarely saw any younger patients, but now I see them regularly. When they turn up, they are shocked because often they haven’t had any symptoms, and because of their age, they are not thinking about cancer.” Source: The Telegraph

MORE YOUNG PEOPLE ARE GETTING CANCER Kate Middleton’s revelation that she is being treated for cancer has spotlighted an alarming increase in cancer among young people. Cancer specialist: “When I started as a cancer surgeon 20 years ago, you rarely saw any younger patients, but now I see them regularly. When they turn up, they are shocked because often they haven’t had any symptoms, and because of their age, they are not thinking about cancer.” Source: The Telegraph

Mario Nawfal

5,703,538 次观看 • 2 年前

Thank you Dyson Cancer Centre and RUH Bath 🏥 for all you do to provide cancer patients with the very best care. Today The Queen spent time with patients and families to hear about their ongoing treatment and the support they have received. 🏥 The Queen also met NHS staff, volunteers and clinicians at the centre to learn about their use of innovative technology. The new Dyson Cancer Centre, which opened in April, provides a nurturing and therapeutic environment. The centre also features a Macmillan Cancer Support Wellbeing Hub. ❤️‍🩹 Wishing the very best to all those continuing cancer treatment on their path to recovery.

Thank you Dyson Cancer Centre and RUH Bath 🏥 for all you do to provide cancer patients with the very best care. Today The Queen spent time with patients and families to hear about their ongoing treatment and the support they have received. 🏥 The Queen also met NHS staff, volunteers and clinicians at the centre to learn about their use of innovative technology. The new Dyson Cancer Centre, which opened in April, provides a nurturing and therapeutic environment. The centre also features a Macmillan Cancer Support Wellbeing Hub. ❤️‍🩹 Wishing the very best to all those continuing cancer treatment on their path to recovery.

The Royal Family

156,261 次观看 • 2 年前

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Sense Receptor

228,469 次观看 • 9 个月前